ARTRYA LIMITED — Investor Relations & Filings

Artrya Limited is a medical technology company focused on the development of artificial intelligence solutions for the detection and management of coronary artery disease. The company's flagship platform, Artrya Salix, utilizes deep learning algorithms to automate the analysis of Computed Tomography Coronary Angiography (CTCA) scans. This technology is designed to assist clinicians by identifying and quantifying key markers of heart disease, including coronary artery stenosis and high-risk vulnerable plaque, which are often difficult to detect through manual review. By providing rapid, non-invasive, and objective assessments, the platform aims to improve diagnostic accuracy, streamline clinical workflows, and support early intervention strategies for patients at risk of major adverse cardiac events. The software integrates into existing clinical environments to provide point-of-care decision support for radiologists and cardiologists.